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Role of Fibroblast Growth Factor (FGF) Signaling in the
Neuroendocrine Control of Human Reproduction
Hichem Miraoui, Ph.D., Andrew Dwyer, M.S.N., and Nelly Pitteloud, M.D.
Abstract
Fibroblast growth factor (FGF) signaling is critical for a broad range of developmental processes.
In 2003, Fibroblast growth factor receptor 1 (FGFR1) was discovered as a novel locus causing
both forms of isolate GnRH Deficiency, Kallmann syndrome ([KS with anosmia ] and normosmic
idiopathic hypogonadotropic hypogonadism [nIHH] eventually accounting for approximately 10%
of gonadotropin-releasing hormone (GnRH) deficiency cases. Such cases are characterized by a
broad spectrum of reproductive phenotypes from severe congenital forms of GnRH deficiency to
reversal of HH. Additionally, the variable expressivity of both reproductive and non-reproductive
phenotypes among patients and family members harboring the identical FGFR1 mutations has
pointed to a more complex, oligogenic model for GnRH deficiency. Further, reversal of HH in
patients carrying FGFR1 mutations suggests potential gene-environment interactions in human
GnRH deficiency disorders.
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Introduction
Puberty is a signal developmental event leading to fertility. Its timing varies greatly in the
general population and is influenced by both genetic and environmental factors (Nathan and
Palmert 2005). In extreme cases of pubertal delay, sexual maturation progresses only
partially or not at all, resulting in the clinical picture of idiopathic hypogonadotropic
hypogonadism (IHH). This rare form of congenital gonadotropin-releasing hormone
(GnRH) deficiency (incidence 1: 10,000 – 1: 40,000) results in incomplete/absent of sexual
maturation and infertility and may present with anosmia (termed Kallmann syndrome [KS])
or with a normal sense of smell (nIHH). These disorders have a male to female ratio of 4:1
(Seminara, Hayes et al. 1998; Hu, Tanriverdi et al. 2003) and are both clinically and
genetically heterogeneous. Notably, studies on the critical roles of mutated genes causing
human GnRH deficiency in the fate specification, proliferation, developmental migration,
secretory function, and/or survival of GnRH neurons have formed the basis for much of our
current understanding of GnRH biology (Bianco and Kaiser 2009). In this review, we focus
on the role of fibroblast growth factor (FGF) signaling pathway in human GnRH deficiency.
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Lessons from FGFR1
In 2003, Fibroblast growth factor receptor 1 (FGFR1) was identified as the first gene
causing the autosomal dominant form of KS by mapping overlapping deletions on
chromosome 8p11-p12 in two KS patients with contiguous gene syndromes (Dode,
Levilliers et al. 2003). Mutations in FGFR1 have now been identified in as many as 10% of
KS cases, mostly in the heterozygous state (Dode, Levilliers et al. 2003; Sato, Katsumata et
al. 2004; Pitteloud, Acierno et al. 2006; Trarbach, Costa et al. 2006; Raivio, Sidis et al.
2009; Sykiotis, Plummer et al. 2010; Shaw, Seminara et al. 2011).
FGFR1 encodes one of 4 FGFRs, which are cell surface receptors of the tyrosine kinase
family. The extracellular immunoglobulin domains 2 and 3 (D2 and D3) determine ligand
binding, affinity, and specificity. Alternative splicing of the carboxy-terminal half of D3
plays a pivotal role in modulating FGF binding specificity via the generation of the isoforms
FGFR1-IIIb and FGFR1-IIIc. The IIIb isoform encoded by exon 8a is expressed in epithelial
tissue, while IIIc isoform enocoded by exon 8b is mesenchymal tissue specific. Activation of
FGFR1 requires dimerization that is mediated by the binding of two FGFs and heparan
sulfate (HS) proteoglycans to the receptor leading to the autophosphorylation of the tyrosine
kinase domains (TKD). These interactions then induce the downstream signaling pathways
(Figure 1) (mitogen activated protein kinase [MAPK], phosphatidylinositide 3 kinase/AKT
[PI3K/AKT], and phospholipase C gamma [PLCγ] pathways)(Mohammadi, Olsen et al.
2005; Miraoui and Marie 2010).
During development, FGFR1 has a critical role in gastrulation, organ specification, and
patterning of many tissues including the brain (Itoh and Ornitz 2011). Further, the FGF
pathway has a crucial role for the development of the olfactory system, with Fgfr1
hypomorphs showing grossly normal cortex development but lacking olfactory bulbs (OB)
(Hebert, Lin et al. 2003). Transgenic mice with targeted expression of dominant-negative
Fgfr1 in the GnRH neurons exhibit delayed puberty and decreased number of GnRH
neurons in the hypothalamus (Tsai, Moenter et al. 2005). These mice studies revealed a role
for FGFR1 in the olfactory system and GnRH ontogeny consistent with the KS patient
phenotype.
While initially thought to underlie only KS (Dode, Levilliers et al. 2003), subsequent reports
revealed that FGFR1 mutations also underlie normosmic IHH (nIHH) (Figure 2)suggesting
a role for FGFR1 beyond olfactory bulb formation (Sato, Katsumata et al. 2004; Kim,
Herrick et al. 2005; Pitteloud, Acierno et al. 2006; Trarbach, Costa et al. 2006; Zenaty,
Bretones et al. 2006; Xu, Qin et al. 2007; Raivio, Sidis et al. 2009). In addition, the
association of identical mutations with both KS and nIHH suggested that these two related
clinical entities might be different manifestations of the same pathological process. GnRH
deficient carrying FGFR1 mutations exhibit variable reproductive phenotypes with different
degrees of GnRH deficiency as evidenced by complete absent puberty with microphallus
and cryptorchidism in some cases, to partial puberty, or the fertile eunuch subset, where
patients are fertile but totally un-virilized (Pitteloud, Meysing et al. 2006; Trarbach, Silveira
et al. 2007). Further, demonstrated reversals of the GnRH deficiency later in adult life in
patients carrying an FGFR1 mutation indicating a gene-environment interaction in this
disorder (Pitteloud, Acierno et al. 2005; Raivio, Falardeau et al. 2007; Raivio, Sidis et al.
2009). Moreover, loss-of-function mutation in FGFR1 can cause delayed puberty in family
members of GnRH deficient probands (Pitteloud, Acierno et al. 2005). Finally, FGFR1
mutations underlying cases of hypothalamic amenorrhea (a form of female infertility caused
by transient GnRH deficiency), a condition previously thought to be functional in nature
(Caronia, Martin et al. 2011), further expands the spectrum of GnRH deficient states
associated with perturbed FGF signaling.
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While patients harboring FGFR1 mutations exhibit a spectrum of reproductive phenotypes,
there is an equally broad range of associated, non-reproductive phenotypes (Table 1).
However, to date, FGFR1 mutations have not been associated with unilateral renal agenesis
as is seen commonly in KS patients with KAL1 mutations, a point that could be used in
targeting genetic testing. This broad array of associated phenotypes mirrors the pleiotropic
roles of FGF signaling in brain, ear, craniofacial structures, kidney, and limb formation
(Beenken and Mohammadi 2009). A number of groups have reported the variable
expressivity of GnRH deficiency and associated phenotypes within and across families
carrying identical FGFR1 mutations (de Roux, Young et al. 1999; Dode, Levilliers et al.
2003; Pitteloud, Acierno et al. 2006; Xu, Qin et al. 2007; Raivio, Sidis et al. 2009). These
puzzling observations are difficult to reconcile with a simple Mendelian (monogenic) model
for KS/nIHH. As such, they presented the first inklings of a more complex genetic
architecture underlying GnRH deficiency.
The human FGFR1 mutations identified in Pfeiffer syndrome and osteoglophonic dysplasia
were shown to be gain-of-function (Muenke, Schell et al. 1994; Roscioli, Flanagan et al.
2000; White, Cabral et al. 2005; Farrow, Davis et al. 2006; Cunningham, Seto et al. 2007;
Sow, Ramli et al. 2010). In contrast, in KS/nIHH, deletions, nonsense and missense
mutations, and splice variants in FGFR1 have been identified, spanning the entire gene
(Kim, Hu et al. 2008). Further, a few KS FGFR1 mutations map to the spliced region of the
receptor affecting the FGFR1c isoform (Pitteloud, Meysing et al. 2006; Dode, Fouveaut et
al. 2007) suggesting a critical role for this isoform in GnRH ontogeny. FGFR1 mutations in
KS are loss-of-function as demonstrated by deletions and stop codons (Figure 2) (Dode,
Levilliers et al. 2003)D. Further, additional structural and functional studies have revealed
FGFR1 missense mutations underlying GnRH deficiency are also loss-of-function, yet
mutants exert their effects via different mechanisms including: i) decreased ligand binding
affinity, ii) altered glycosylation resulting in decreased cell surface expression and likely
abnormal receptor trafficking, and iii) decreased tyrosine kinase activity. Importantly, the
severity of the loss-of-function does not accurately predict the severity of the reproductive
phenotypes (Table 2). In summary, human genetics has uncovered a previously uncharted
role of FGFR1 in the neuroendocrine control of human reproduction.
Lessons from FGF8
The L342S FGFR1 mutation, was originally found in a proband with KS, absent puberty,
and cleft palate. Such a severe phenotype was suggestive of a severe FGFR1 loss-of-
function mutation. Yet the mutant showed normal binding to FGF2 (a universal FGF ligand)
and normal MAP kinase (MAPK) activation upon FGF2 stimulation (Pitteloud, Quinton et
al. 2007). Further mapping of the L342S FGFR1 amino-acid mutation onto the crystal
structure of the extracellular domain of FGFR1 with FGF8 predicted the L342S would cause
a dramatic decrease in FGF8b-FGFR1c binding. This structural prediction was confirmed
via surface plasmon resonance, demonstrating that L342S was indeed a loss of function
mutant which selectively and dramatically reduced binding affinity of FGF8 but did not
affect FGF1 or FGF2 (Pitteloud, Quinton et al. 2007). This single FGFR1 mutation was
prismatic for elucidating FGF8 as a critical FGF ligand for FGFR1 in GnRH ontogeny and
uncovered a new area of investigation.
Subsequently, a large population of more than 400 GnRH deficient patients was screened for
mutations in FGF8 identifying both heterozygous and homozygous FGF8 mutations in KS
and nIHH patients (Falardeau, Chung et al. 2008), thus confirming this as a novel locus for
GnRH deficiency (Figure 3). Subjects harboring FGF8 mutations similarly display a broad
spectrum of pubertal development ranging from absent, to partial, to complete puberty (in a
male with adult onset hypogonadotropic hypogonadism (Nachtigall, Boepple et al. 1997)).
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Their associated non-reproductive phenotypes are equally variable including hearing loss
and a range of skeletal features (high arched palate, cleft lip/palate, severe osteoporosis,
camptodactyly, and hyperlaxity of the digits). Notably, variable expressivity among family
members is evident with anosmia, delayed puberty, and IHH present in family members
harboring the identical heterozygous R127X mutation in FGF8. Indeed, this theme of
incomplete penetrance was also displayed in a report of a Brazilian family including an
asymptomatic father and his 5 affected children, with variable phenotypes ranging from IHH
with cleft lip/palate, KS, IHH, neurosensorial deafness and delayed puberty all of whom
harbor the identical heterozygous stop codon in FGF8 and thus a nonfunctional ligand
(Trarbach, Abreu et al. 2010). Notably, the first heterozygous FGF8 mutation identified in
humans was reported in relation to a male with non-syndromic cleft lip and palate whose
reproductive status was unknown (Riley, Mansilla et al. 2007) (Figure 3).
FGF8 is a powerful morphogen during development not only for the olfactory placode, but
also for the anterior cortex, limbs, ears, and kidney. Thus, its expression and activity are
under tight temporal and spatial regulation during development (Niehrs and Meinhardt
2002). Fgf8 hypomorphic mice die at birth with midline, cerebellar, and cardiac defects
(Meyers, Lewandoski et al. 1998). Interestingly, fgf8 expression overlaps with fgfr1 as Fgf8
mRNA is found in the ectoderm region ventral/lateral of the telencephalic commissural plate
on E9.5, which later forms the olfactory placode (Crossley and Martin 1995; Kawauchi,
Shou et al. 2005). Murine expression studies suggest that fgf8 signaling is critically
important for the induction and differentiation of the mouse olfactory placode (Chung,
Moyle et al. 2008; Chung and Tsai 2010).
Human FGF8 genetics pointed to a critical role for FGF8 in GnRH ontogeny. Indeed, Fgf8
hypomorph mice exhibit absent GnRH neurons in the hypothalamus and lack fate
specification of GnRH neurons in the olfactory placode with no signs of apoptosis,
supporting a critical role for FGF8 in GnRH specification. The heterozygous mice had
significantly decreased numbers of GnRH neurons, implying an exquisite sensitivity of the
GnRH neuron population to Fgf8 dosage (Falardeau, Chung et al. 2008). These murine
studies are consistent with olfactory and reproductive phenotypes observed in patients
harboring heterozygous FGF8 mutations.
Modes of inheritance and oligogenicity
Much like the genetic story of Bardet-Biedl syndrome (BBS), wherein a “monogenic”
disorder was subsequently shown to be oligogenic in nature with mutations in more than one
BBS gene (Badano and Katsanis 2002), oligogenicity underlying human GnRH deficiency
has become an emerging theme. Human GnRH deficiency has been traditionally considered
a monogenic disorder. Rare variants in FGFR1 were first thought to cause autosomal
dominant form of KS (Dode, Levilliers et al. 2003). However, reports of the same mutation
(i.e. R622X FGFR1 in 3 unrelated kindreds (Dode, Levilliers et al. 2003; Pitteloud, Acierno
et al. 2005; Xu, Qin et al. 2007)) (Figure 4) demonstrate significant phenotypic variability
both within and across IHH family members carrying the identical mutation and incomplete
penetrance. Such variable expressivity has been noted by others (Parenti, Rizzolo et al.
1995; de Roux, Young et al. 1999), supporting the notion that a genotype at a single locus
cannot reliably predict the phenotypic manifestations of the various family members
harboring the same mutation(Pitteloud, Acierno et al. 2005) (Pitteloud, Acierno et al. 2006;
Pitteloud, Meysing et al. 2006). Subsequently, several case reports of KS/nIHH individuals
carrying two gene defects have been published (Pitteloud, Quinton et al. 2007; Pitteloud,
Durrani et al. 2010). Subsequently, nearly 400 GnRH deficient patients were studied
systematically for the known IHH loci demonstrating that oligogenicity is as common as
homozygosity/compound heterozygosity in human GnRH deficiency (Sykiotis, Plummer et
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al. 2010). Notably, the major player identified in digenic or oligogenic mutations was
FGFR1, supporting the central role of FGF signaling in human GnRH deficiency. Further,
these reports raise the question whether heterozygous FGFR1 mutations per se can cause
GnRH deficiency or whether additional gene defects and/or environmental cues are
required.
Future directions and conclusions
During the last decade, human and murine models have demonstrated a critical role for FGF
signaling in GnRH ontogeny. Studying FGFR1/FGF8 mutations in KS/nIHH has been
critical in challenging the traditional monogenic model of these disorders and pointing to a
role for complex genetics. However, the precise molecular mechanism underlying the effect
of loss-of-function FGF8/FGFR1 mutations on GnRH ontogeny remain largely unknown
and further biologic investigation is required to decipher the precise role of this signaling
system in human reproduction.
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Figure 1. Pathways downstream of FGFR signaling
FGF/FGFR binding leads to activation of several signal transduction pathways including
phospholipase Cγ (PLCγ), mitogen-activated protein kinases (MAPK), and
phosphatidylinositol 3-kinase (PI3K). FGF signaling cascades are implicated in the control
of several cellular processes including cell proliferation, differentiation, and survival in
multiple tissues and cell lines.
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Figure 2. Schematic representing the structural domains of FGFR1 protein with identified
human mutations (GnRH deficiency and bone phenotypes)
Signal peptide (SP), acidic box (AB), immunoglobulin like domains (D 1–3), heparan
sulfate (yellow crescent), 2nd half of D3 ([gray crescent], determines FGFR1 c or b isoform),
transmenbrane domain (TM), tyrosine kinase domains (TKD), and C-terminal tail (CT) are
shown. Human FGFR1 mutations exhibiting a reproductive phenotype (GnRH deficiency)
are identified above the schematic while bone phenotypes are depicted below.
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Figure 3. Schematic of genomic structure and differential splicing of the human FGF8 gene with
human mutations identified to date (GnRH deficiency and midline defects)
(A) Structure of the FGF8 gene: Boxes denote exons; lines denote introns. (B) Schematic of
the 4 FGF8 isoforms identified in humans, which differ with regard to the inclusion of exon
1C and part of exon 1D. Most of the conserved FGF core is encoded by exons 2 and 3.
Numbers above exons denote the amino acid numbering for each isoform. The mutations
identified to date are indicated by arrows and are numbered according to the FGF8f protein
isoform. The two mutations in red denote midline defects (D94H [D73H in FGF8b
numbering] = nonsyndromic cleft lip/palate (Riley, Mansilla et al. 2007); T229M =
holoprosencephaly (Arauz, Solomon et al. 2010)). Asterisk denotes the homozygous change
(adapted from Falardeau et. al. (Falardeau, Chung et al. 2008)).
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Figure 4. Variable expressivity in three kindreds harboring the identical R622X FGFR1
mutation
A single genotype cannot reliable predict the phenotype: The identical mutation presents as
fully penetrant normosmic IHH in pedigree 1(Xu, Qin et al. 2007). Pedigree 2 shows both
mild and severe phenotypes (asymptomatic carrier and Kallmann syndrome [KS] with cleft
lip/palate respectively) (Dode, Levilliers et al. 2003). Pedigree 3 displays variable
phenotypes of R622X including anosmia only, delayed puberty, and KS. Notably, the KS
subject exhibited a reversal (Pitteloud, Acierno et al. 2005).
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